Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 18 2020 - 8:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: November 2020
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name into
English)
14 Einstein Street, Nes Ziona, Israel 7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On November 18, 2020, Enlivex Therapeutics Ltd.,
a company organized under the laws of the State of Israel, issued a press release announcing a positive two-year clinical outcome
following the first Allocetra™ treatment of a hospitalized patient with erosive osteoarthritis, a rare bone disease, which
has no approved nor effective treatment options and typically involves rapid destruction of hip and shoulder bones. A copy of such
press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Enlivex Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/ Oren Hershkovitz
|
|
Name:
Title:
|
Oren Hershkovitz
Chief Executive Officer
|
Date: November 18, 2020
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Sep 2023 to Sep 2024